CIK 0001439222
- Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-01-28 | Cantley Lewis Clayton Jr. Director | Sale | −625 | $44.33 | $28K | 132,340 |
| 2016-01-07 | Biller Scott Chief Scientific Officer | Exercise or conversion | +15,000 | $0.47 | $7K | 49,070 |
| 2016-01-07 | Biller Scott Chief Scientific Officer | Exercise or conversion · Stock option (right to buy) | −15,000 | 293,471 | ||
| 2016-01-07 | Schenkein David P Chief Executive Officer | Exercise or conversion | +20,000 | $0.30 | $6K | 272,272 |
| 2016-01-07 | Schenkein David P Chief Executive Officer | Exercise or conversion · Stock option (right to buy) | −20,000 | 895,501 | ||
| 2016-01-05 | Schenkein David P Chief Executive Officer | Exercise or conversion | +10,000 | $0.30 | $3K | 252,272 |
| 2016-01-05 | Schenkein David P Chief Executive Officer | Exercise or conversion · Stock option (right to buy) | −10,000 | 915,501 | ||
| 2016-01-04 | Higgons John Duncan Chief Operating Officer | Exercise or conversion | +57,024 | $2.34 | $133K | 118,859 |
| 2016-01-04 | Higgons John Duncan Chief Operating Officer | Exercise or conversion | +1,975 | $31.64 | $62K | 120,834 |
| 2016-01-04 | Higgons John Duncan Chief Operating Officer | Exercise or conversion · Stock option (right to buy) | −57,024 | 182,088 | ||
| 2016-01-04 | Higgons John Duncan Chief Operating Officer | Exercise or conversion · Stock option (right to buy) | −1,975 | 180,113 | ||
| 2016-01-04 | Schenkein David P Chief Executive Officer | Exercise or conversion | +10,000 | $0.30 | $3K | 242,272 |
| 2016-01-04 | Schenkein David P Chief Executive Officer | Exercise or conversion · Stock option (right to buy) | −10,000 | 925,501 | ||
| 2015-12-31 | Biller Scott Chief Scientific Officer | Exercise or conversion | +5,500 | $31.64 | $174K | 39,570 |
| 2015-12-31 | Biller Scott Chief Scientific Officer | Sale | −5,500 | $65.27 | $359K | 34,070 |
| 2015-12-31 | Biller Scott Chief Scientific Officer | Exercise or conversion · Stock option (right to buy) | −5,500 | 308,471 | ||
| 2015-12-29 | Cantley Lewis Clayton Jr. Director | Sale | −2,670 | $66.16 | $177K | 132,967 |
| 2015-12-29 | Cantley Lewis Clayton Jr. Director | Sale | −2,670 | $66.11 | $177K | 132,965 |
| 2015-12-28 | Cantley Lewis Clayton Jr. Director | Sale | −2,662 | $63.73 | $170K | 135,637 |
| 2015-12-28 | Cantley Lewis Clayton Jr. Director | Sale | −2,662 | $63.72 | $170K | 135,635 |
Page 83 of 93 · 1,853 trades